View in EDS

Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.

Saved in:
Bibliographic Details
Title: Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.
Authors: Ariaee A; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Noueihad K; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Hunter A; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Wignall A; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Wardill HR; Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia; Supportive Oncology Research Group, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia., Davies M; Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia; Supportive Oncology Research Group, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia., Prestidge CA; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia., Joyce P; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia. Electronic address: paul.joyce@unisa.edu.au.
Source: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2026 Apr 10; Vol. 392, pp. 114711. Date of Electronic Publication: 2026 Feb 09.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41672308
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ariaee+A%22">Ariaee A</searchLink>; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.<br /><searchLink fieldCode="AU" term="%22Noueihad+K%22">Noueihad K</searchLink>; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.<br /><searchLink fieldCode="AU" term="%22Hunter+A%22">Hunter A</searchLink>; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.<br /><searchLink fieldCode="AU" term="%22Wignall+A%22">Wignall A</searchLink>; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.<br /><searchLink fieldCode="AU" term="%22Wardill+HR%22">Wardill HR</searchLink>; Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia; Supportive Oncology Research Group, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.<br /><searchLink fieldCode="AU" term="%22Davies+M%22">Davies M</searchLink>; Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia; Supportive Oncology Research Group, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia.<br /><searchLink fieldCode="AU" term="%22Prestidge+CA%22">Prestidge CA</searchLink>; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.<br /><searchLink fieldCode="AU" term="%22Joyce+P%22">Joyce P</searchLink>; Translational Nanomedicines and Biotherapeutics, University of South Australia, Adelaide, SA 5000, Australia; Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia. Electronic address: paul.joyce@unisa.edu.au.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228607908%22">Journal of controlled release : official journal of the Controlled Release Society</searchLink> [J Control Release] 2026 Apr 10; Vol. 392, pp. 114711. <i>Date of Electronic Publication: </i>2026 Feb 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Publishers%22">Elsevier Science Publishers </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8607908 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-4995 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201683659%22">01683659 </searchLink><i>NLM ISO Abbreviation: </i>J Control Release <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41672308
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jconrel.2026.114711
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 114711
    Titles:
      – TitleFull: Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ariaee A
      – PersonEntity:
          Name:
            NameFull: Noueihad K
      – PersonEntity:
          Name:
            NameFull: Hunter A
      – PersonEntity:
          Name:
            NameFull: Wignall A
      – PersonEntity:
          Name:
            NameFull: Wardill HR
      – PersonEntity:
          Name:
            NameFull: Davies M
      – PersonEntity:
          Name:
            NameFull: Prestidge CA
      – PersonEntity:
          Name:
            NameFull: Joyce P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 04
              Text: 2026 Apr 10
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1873-4995
          Numbering:
            – Type: volume
              Value: 392
          Titles:
            – TitleFull: Journal of controlled release : official journal of the Controlled Release Society
              Type: main
ResultId 1